Related Experiment Video

Updated: Jun 12, 2026

Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain
08:32

Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain

Published on: January 4, 2018

Genome-wide expression profiling revealed peripheral effects of cannabinoid receptor 1 inverse agonists in improving

Wenqing Zhao1, Olivia Fong, Eric S Muise

  • 1Department of Molecular Profiling, Merck Research Laboratories, 126 E. Lincoln Ave., Rahway, NJ 07065, USA. wenqing_zhao@merck.com

Molecular Pharmacology
|June 10, 2010
PubMed

Insights

Inhibiting cannabinoid receptor 1 (CB1) with AM251 reduced body weight and improved metabolism by altering gene expression in liver and fat. This suggests peripheral CB1 inhibition impacts key metabolic pathways.

Area of Science:

  • Metabolic research
  • Pharmacology
  • Obesity research

Background:

  • Cannabinoid receptor 1 (CB1) inhibition shows promise for weight reduction and metabolic improvement.
  • Peripheral effects of CB1 inhibition are understood through studies in diet-induced obese and liver-specific CB1 knockout mice.

Purpose of the Study:

  • To systematically investigate gene expression changes in peripheral tissues of diet-induced obese mice treated with the CB1 inverse agonist AM251.
  • To understand the molecular mechanisms underlying the peripheral effects of CB1 inhibition.

Main Methods:

  • Diet-induced obese mice were treated with the CB1 inverse agonist AM251.
  • Gene expression profiling was performed on liver and adipose tissues.
  • Analysis focused on key metabolic pathways including fatty acid and cholesterol synthesis, and inflammatory signaling.

Main Results:

  • CB1 receptor inhibition down-regulated genes in de novo fatty acid and cholesterol synthesis pathways (SREBP1, SREBP2) in liver and adipose tissue.
  • Genes involved in fatty acid beta-oxidation were up-regulated, potentially via peroxisome proliferator-activated receptor alpha (PPARalpha) activation.
  • In adipose tissue, CB1 inhibition down-regulated tumor necrosis factor alpha signaling and potentially activated PPARgamma, improving insulin sensitivity.

Conclusions:

  • Peripheral CB1 receptor inhibition by AM251 modulates gene expression in key metabolic pathways.
  • These changes include reduced lipogenesis, enhanced fatty acid oxidation, and improved insulin sensitivity, offering therapeutic potential for obesity and metabolic disorders.

More Related Videos

Live Images of GLUT4 Protein Trafficking in Mouse Primary Hypothalamic Neurons Using Deconvolution Microscopy08:47

Live Images of GLUT4 Protein Trafficking in Mouse Primary Hypothalamic Neurons Using Deconvolution Microscopy

Published on: December 7, 2017

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice11:10

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice

Published on: November 16, 2011

Related Concept Videos

Insulin: The Receptor and Signaling Pathways01:28

Insulin: The Receptor and Signaling Pathways

Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but this inhibition is released...
Spare Receptors01:30

Spare Receptors

Some receptors remain unoccupied even when an agonist produces a maximal response. Such empty ones are called spare receptors. In presence of spare receptors the maximum effect of an agonist drug is achieved with fewer than 100% of the receptors being occupied. To determine the presence of spare receptors, scientists often compare the concentration of the drug needed to produce 50% of the maximum effect (EC50) with the concentration of the drug needed to occupy 50% of the receptors (Kd). If the...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
G Protein-coupled Receptors01:15

G Protein-coupled Receptors

G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
Hormones Regulating Blood Glucose01:16

Hormones Regulating Blood Glucose

Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
GPCRs Regulate Adenylyl Cylase Activity01:09

GPCRs Regulate Adenylyl Cylase Activity

Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of cells.
Two...